For the quarter ending 2025-09-30, GLUE had $138,914K increase in cash & cash equivalents over the period. $99,777K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -27,081 | 34,590 |
| Stock-based compensation expense | 4,364 | 10,192 |
| Depreciation | 2,095 | 4,173 |
| Net accretion of discounts/premiums on marketable securities | -466 | -1,766 |
| Gain on disposal of property and equipment | 0 | 59 |
| Other receivables | 2,596 | 2,196 |
| Accounts receivable | - | 0 |
| Prepaid expenses and other assets | -941 | 1,713 |
| Accounts payable | 8,880 | -11,976 |
| Accrued expenses and other current liabilities | 4,194 | -5,077 |
| Defined benefit plan liability | -235 | -957 |
| Right-of-use assets and operating lease liabilities | -354 | -427 |
| Deferred revenue | 110,216 | -106,910 |
| Net cash provided by (used in) operating activities | 100,428 | -80,212 |
| Purchases of property and equipment | 651 | 3,282 |
| Purchases of marketable securities | 65,969 | 157,047 |
| Proceeds from maturities of marketable securities | 104,758 | 85,424 |
| Net cash used in investing activities | 38,138 | -74,905 |
| Proceeds from sale of common stock pursuant to the at-the-market sales agreement, net of underwriter's discount of 29 | 0 | 0 |
| Proceeds from underwritten public offering , net of underwriter's discount of 3,000 | 0 | 0 |
| Proceeds from the issuance of pre-funded warrants | 0 | 0 |
| Payment of common stock and pre-funded warrant issuance costs | 0 | 0 |
| Proceeds from exercise of employee stock options | 348 | 14 |
| Proceeds from employee stock purchase plan | 0 | 365 |
| Net cash provided by financing activities | 348 | 379 |
| Net decrease in cash, cash equivalents and restricted cash | 138,914 | -154,738 |
| Cash and cash equivalents at beginning of period | 229,117 | - |
| Cash and cash equivalents at end of period | 213,293 | - |
Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE)